It has been shown that another mutation in APOC3 rs2070667 is responsible for exacerbating the pathological factors associated with NAFLD, mainly because of its inhibitory effect on PUFA-containing TG levels in serum [55]. Here, APOC3 is linked to metabolic dysfunction-associated steatotic liver disease.